2023-08-01 16:20:03 ET
- Exact Sciences press release ( NASDAQ: EXAS ): Q2 GAAP EPS of -$0.45 beats by $0.06 .
- Revenue of $622.1M (+19.3% Y/Y) beats by $20.97M .
- Core revenue was $617.5 million, an increase of 24 percent
- Screening revenue was $462.8 million, an increase of 31 percent
- Precision Oncology revenue was $157.2 million, an increase of 2 percent, or 7 percent on a core revenue basis
- COVID-19 testing revenue was $2.1 million, a decrease of 84 percent
-
2023 outlook
The company anticipates revenue of $2.441-$2.466 billion Vvs $2.42B consensus during 2023, assuming:
- Screening revenue of $1.820-$1.835 billion,
- Precision Oncology revenue of $615-$625 million, and
- COVID-19 testing revenue of $6 million.
Revenue guidance has been raised from the previously expected range of $2.380-$2.420 billion, which assumed:
- Screening revenue of $1.770-$1.795 billion,
- Precision Oncology revenue of $605-$620 million, and
- COVID-19 testing revenue of $5 million.
For further details see:
Exact Sciences GAAP EPS of -$0.45 beats by $0.06, revenue of $622.1M beats by $20.97M